The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
208 - Hi there I was wondering if we would need to PAAB-approval formulary announcements to physicians if conditions for benefit on the formulary in their province are to be listed in the announcement. Example for coverage on provincial plan: Patients are over 4 years old. Cared by a physician experienced in managing seizures associated with LGS. Already on two or more antiepileptic drugs in whom topirimate, lamotrigine and other expensive drugs are ineffective or inappropriate. Thank you
FYI post-approval change/preclearance exemption/what requires review/PAAB scope
1
Posts
1
Posters
292
Views
1
Watching
